Yamamura T, et al. A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD). ECTRIMS 2018, abstract 323.
Cognitiespreekuur MS van start
apr 2017 | Multipele Sclerose